Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Lupeng Pharmaceutical Ltd. clinical trials
The registry lists 20 studies whose lead sponsor is Lupeng Pharmaceutical Ltd. or one of 2 companies grouped under it. 12 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 14, 2026.
Keep track of what changes. Save the Lupeng Pharmaceutical Ltd. studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Lupeng Pharmaceutical Ltd..
- Guangzhou Lupeng Pharmaceutical Company LTD.16 studies →Subsidiary
Something wrong?
- Newave Pharmaceutical Inc4 studies →Subsidiary
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 20 of 20.
- A Study of LP-168 in Participants With Relapse or Refractory B-Cell LymphomaRecruitingNCT04993690Phase 1
Sponsor listed in the registry: Guangzhou Lupeng Pharmaceutical Company LTD.
- A Study to Assess Safety and Preliminary Efficacy of LP-108 Combined With Azacitidine In Subjects With AML, MDS, CMMLRecruitingNCT05641259Phase 1
Sponsor listed in the registry: Guangzhou Lupeng Pharmaceutical Company LTD.
- A Study of Rocbrutinib Combined With R-GemOx in Patients With Relapsed or Refractory Diffuse Large B-cell LymphomaRecruitingNCT07570017Phase 1
Sponsor listed in the registry: Guangzhou Lupeng Pharmaceutical Company LTD.
- A Study of Rocbrutinib in PRL-Positive Relapsing-Remitting Multiple SclerosisRecruitingNCT07776743Phase 2
Sponsor listed in the registry: Guangzhou Lupeng Pharmaceutical Company LTD.
- ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLLRecruitingNCT07342478Phase 3
Sponsor listed in the registry: Newave Pharmaceutical Inc
- A Study of Lacutoclax (LP-108) in Patients With Relapsed/Refractory CLL/SLLRecruitingNCT07609823Phase 2
Sponsor listed in the registry: Guangzhou Lupeng Pharmaceutical Company LTD.
- A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell MalignanciesRecruitingNCT07609862Phase 1/2
Sponsor listed in the registry: Guangzhou Lupeng Pharmaceutical Company LTD.
- Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.RecruitingNCT04771572Phase 1
Sponsor listed in the registry: Newave Pharmaceutical Inc
- A Study Evaluating the Effects of Itraconazole or Rifampin on the Pharmacokinetic Characteristics of Rocbrutinib TabletRecruitingNCT07374224Phase 1
Sponsor listed in the registry: Guangzhou Lupeng Pharmaceutical Company LTD.
- Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.RecruitingNCT04775745Phase 1
Sponsor listed in the registry: Newave Pharmaceutical Inc
- A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell LymphomaRecruitingNCT07377578Phase 3
Sponsor listed in the registry: Guangzhou Lupeng Pharmaceutical Company LTD.
- A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell LymphomaRecruitingNCT07189065Phase 2
Sponsor listed in the registry: Guangzhou Lupeng Pharmaceutical Company LTD.
- Phase Ib Study of Rocbrutinib in Combination With R-CHOP in Patients With Newly Diagnosed B-cell Non-Hodgkin LymphomaActive, not recruitingNCT06251180Phase 1
Sponsor listed in the registry: Guangzhou Lupeng Pharmaceutical Company LTD.
- Dose-Escalation Study of Oral Administration of LP-108 as Monotherapy and in Combination With Azacitidine in Patients With Relapsed or Refractory MDS, CMML, or AMLCompletedNCT04139434Phase 1
Sponsor listed in the registry: Newave Pharmaceutical Inc
- A Study of Rocbrutinib in Participants With Relapse or Refractory Mantle Cell LymphomaActive, not recruitingNCT05716087Phase 2
Sponsor listed in the registry: Guangzhou Lupeng Pharmaceutical Company LTD.
- A Study of LP-118 in Patients With Advanced TumorsCompletedNCT05025358Phase 1
Sponsor listed in the registry: Guangzhou Lupeng Pharmaceutical Company LTD.
- A Study of LP-128 Capsules in Healthy SubjectsActive, not recruitingNCT05130567Phase 1
Sponsor listed in the registry: Guangzhou Lupeng Pharmaceutical Company LTD.
- The Mass Balance Study of LP-168 in Healthy SubjectsCompletedNCT06126861Phase 1
Sponsor listed in the registry: Guangzhou Lupeng Pharmaceutical Company LTD.
- A Food Effect Study of LP-168 Tablets in Healthy SubjectsCompletedNCT05917964Phase 1
Sponsor listed in the registry: Guangzhou Lupeng Pharmaceutical Company LTD.
- A Study of LP-168 in Healthy VolunteersCompletedNCT05432713Phase 1
Sponsor listed in the registry: Guangzhou Lupeng Pharmaceutical Company LTD.